Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancers (2021) Vol. 13, Iss. 3, pp. 558-558
Open Access | Times Cited: 230

Showing 1-25 of 230 citing articles:

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Dongrui Wang, Xianlin Wu, Yingli Sun
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 282
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Adel Naimi, Rebar N. Mohammed, Ahmed Raji, et al.
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 272
FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
Ye Wang, Zhuang Tong, Wen‐Hua Zhang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 147
Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review
Teklie Mengie Ayele, Zelalem Tilahun Muche, Awgichew Behaile Teklemariam, et al.
Journal of Inflammation Research (2022) Vol. Volume 15, pp. 1349-1364
Open Access | Times Cited: 124
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
Alessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 6, pp. 549-555
Closed Access | Times Cited: 111
Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2022) Vol. 16, Iss. 4, pp. 333-339
Closed Access | Times Cited: 79
Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
Norah A. Alturki
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4301-4301
Open Access | Times Cited: 50
Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application
Mingyang Li, Lei Li, Jianyi Zheng, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 47
Advances and prospects of biomarkers for immune checkpoint inhibitors
Hirohito Yamaguchi, Jung-Mao Hsu, Linlin Sun, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 7, pp. 101621-101621
Open Access | Times Cited: 24
Training and experimental validation a novel anoikis- and epithelial‒mesenchymal transition-related signature for evaluating prognosis and predicting immunotherapy efficacy in gastric cancer
Cheng Zeng, Chang Xu, Yuhan Wei, et al.
Journal of Cancer (2025) Vol. 16, Iss. 4, pp. 1078-1100
Open Access | Times Cited: 2
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 4, pp. 343-350
Closed Access | Times Cited: 101
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
Alessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 4, pp. 415-423
Closed Access | Times Cited: 91
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review
Alessandro Rizzo, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100354-100354
Open Access | Times Cited: 88
First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!”
Alessandro Rizzo, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100335-100335
Open Access | Times Cited: 80
Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer
Alessandro Rizzo, Giovanni Brandi
Expert Review of Gastroenterology & Hepatology (2021) Vol. 15, Iss. 5, pp. 547-554
Closed Access | Times Cited: 78
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100337-100337
Open Access | Times Cited: 76
Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker
Chi Zhang, Yuanxiao Zeng, Xiuchen Guo, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 67
Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment
Paula Dobosz, Maria Stępień, Anna Golke, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2847-2847
Open Access | Times Cited: 61
The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis
Biao Ning, Yixin Liu, Miao Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 55
Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma
Taek Chung, Young Nyun Park
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 49
CCNA2 as an Immunological Biomarker Encompassing Tumor Microenvironment and Therapeutic Response in Multiple Cancer Types
Aimin Jiang, Ye Zhou, Wenliang Gong, et al.
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-35
Open Access | Times Cited: 43
NCAPG2 could be an immunological and prognostic biomarker: From pan-cancer analysis to pancreatic cancer validation
Qi Wang, Zhangzuo Li, Shujing Zhou, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
CD74 as a prognostic and M1 macrophage infiltration marker in a comprehensive pan-cancer analysis
Ruo Qi Li, Lei Yan, Ling Zhang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges
Alessandro Rizzo, Vincenzo Dadduzio, Lucia Lombardi, et al.
Current Oncology (2021) Vol. 28, Iss. 5, pp. 3393-3402
Open Access | Times Cited: 46
An Integrative Human Pan-Cancer Analysis of Cyclin-Dependent Kinase 1 (CDK1)
Xuanyou Liu, Hao Wu, Zhenguo Liu
Cancers (2022) Vol. 14, Iss. 11, pp. 2658-2658
Open Access | Times Cited: 32
Page 1 - Next Page

Scroll to top